Abstract
This study aimed to assess trends in systemic anticancer therapy (Rx) utilization in patients 66 years or older with advanced (stage III/IV) cutaneous melanoma from 2008 to 2017, a period of rapid expansion of treatment options.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
